Zhao Yajie, Shen Liangfang, Chen Xi, Qian Yujie, Zhou Qin, Wang Ying, Li Kai, Liu Miaomiao, Zhang Sai, Huang Xinqiong
Department of Oncology, Xiangya Hospital, Central South University, Hunan Province, P.R. China.
Guangzhou Centers for Disease Control and Prevention, Guangdong Province, P.R. China.
Histol Histopathol. 2015 Nov;30(11):1313-20. doi: 10.14670/HH-11-627. Epub 2015 May 4.
Our study aimed to investigate the association of Pyruvate Kinase isozyme type M2 (PKM2) with radiation resistance in locally advanced cervical squamous cell carcinoma (LACSCC). We retrospectively reviewed 132 female patients who received primary radiation therapy to treat LACSCC at Federation Internationale of Gynecologie and Obstetrigue (FIGO) stages IB-IVA. Forty-seven patients with progression free survival (PFS) of less than 36 months were regarded to have radiation resistance. Eighty-five patients with PFS no less than 36 months were regarded as radiation sensitive. Using immunohistochemistry, we found that the overexpression rate of PKM2 in radiation resistant and radiation sensitive patients was 87.2% and 57.6%, respectively, and the difference was statistically significant (p<0.001). The 5-year progress free survival rates in patients with low and high expression of PKM2 was 80.4% and 60.5%, respectively, and the difference was statistically significant (p=0.008). Multivariate Cox regression analysis identified that high expression of PKM2 is an independent negative prognostic factor in cervical cancer patients [Hazard ratio (95% CI), 2.888 (1.347, 6.194) p=0.006]. These results demonstrate that overexpression of PKM2 contributes to radiation resistance and acts a poor prognosis indicator in patients with LACSCC.
我们的研究旨在探讨丙酮酸激酶M2型（PKM2）与局部晚期宫颈鳞状细胞癌（LACSCC）放射抗性之间的关联。我们回顾性分析了132例在国际妇产科联合会（FIGO）分期为IB-IVA期的LACSCC患者，这些患者接受了原发性放射治疗。47例无进展生存期（PFS）少于36个月的患者被视为具有放射抗性。85例PFS不少于36个月的患者被视为放射敏感。通过免疫组织化学，我们发现PKM2在放射抗性和放射敏感患者中的过表达率分别为87.2%和57.6%，差异具有统计学意义（p<0.001）。PKM2低表达和高表达患者的5年无进展生存率分别为80.4%和60.5%，差异具有统计学意义（p=0.008）。多因素Cox回归分析确定PKM2高表达是宫颈癌患者的独立不良预后因素[风险比（95%CI），2.888（1.347，6.194），p=0.006]。这些结果表明，PKM2的过表达导致放射抗性，并在LACSCC患者中作为不良预后指标。
